Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live

United States & Moderna

14 shared events · Importance 6 · Last updated Jun 11, 2026

Importance
6
Shared Events
14
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the NewsDesk Dashboard
60
Accidents
United States: United States>>> has bolstered precautions, including screening air passengers and suspending visa services, and has provided $13 million in assistance for the response.
Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
60
International
United States: The United States>>> has announced additional aid to the Democratic Republic of the Congo>>> for the Ebola response and has implemented temporary travel bans for non-citizens from affected countries. It also plans to establish a quarantine facility in Kenya>>> for exposed Americans.
Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.
May 21, 2026 · 627 articles
55
Business
United States: The United States is the host country for these unicorn companies, benefiting significantly from immigrant entrepreneurship in its technology and startup sectors.
Moderna: Moderna is an immigrant-founded unicorn company that has gone public since 2016.
Jun 04, 2026 · 6 articles
50
Accidents
United States: The United States>>> has pledged financial aid and is monitoring the Ebola outbreak, with some of its citizens exposed or infected, but its previous aid cuts and withdrawal from the World Health Organization>>> have been criticized for weakening global health response capacity.
Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.
May 18, 2026 · 505 articles
30
Tech
United States: United States>>> is one of the countries where patients were enrolled for the KEYNOTE-942 trial, contributing to the global scope of the research. Its involvement highlights its participation in international medical studies and its significant burden of skin cancer cases.
Moderna: As the manufacturer of intismeran, Moderna>>> is a key beneficiary of the positive clinical trial results, which could lead to increased revenue and market share in cancer treatment. The success of intismeran validates Moderna>>>'s mRNA vaccine platform for oncology applications.
Jun 01, 2026 · 6 articles
0
Regulatory
Moderna: Moderna, a manufacturer of widely used COVID-19 vaccines, did not immediately comment on the new policy.
May 20, 2025 · 12 articles
0
Regulatory
Moderna: Moderna had $766 million in funding for its mRNA-1018 vaccine canceled by the United States — United States Department of Health and Human Services, adding uncertainty to the vaccine's development.
May 29, 2025 · 6 articles
0
Regulatory
Feb 18, 2026 · 6 articles
0
Regulatory
Feb 18, 2026 · 9 articles
0
Business
Apr 01, 2026 · 6 articles
0
Domestic
Mar 16, 2026 · 22 articles
0
Domestic
May 08, 2026 · 114 articles
0
Domestic
May 02, 2026 · 30 articles
0
Domestic
Apr 22, 2026 · 6 articles
NEWSDESK
Explore this relationship live

Track how United States and Moderna interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.